Diagnostic Model Developed for Impending Death in Patients with Cancer
the Cancer Therapy Advisor take:
A diagnostic model for impending death within 3 days was developed for patients with cancer, according to an article published online in the journal Cancer.
In this study, the investigators systematically documented 62 physical signs every 12 hours from patient admission to acute palliative care units (APCUs) to death or discharge for a total of 357 patients diagnosed with advanced cancer.
Results showed 322 out of the 357 patients (90%) had complete data for all signs. The 3-day mortality rate for these patients was 24% on admission to APCUs.
A model for impending death was developed with two variables acting as its foundation: Palliative Performance Scale (PPS) and drooping of nasolabial folds. Moreover, the model was based on 4 terminal leaves: PPS score less than or equal to 20% and drooping of nasolabial folds present, PPS score less than or equal to 20% and drooping of nasolabial folds absent, PPS score of 30% to 60%, and PPS score greater than or equal to 70%.
The authors determined the 3-day mortality rates for the four terminal leaves to be 94%, 42%, 16%, and 3%, respectively.
Furthermore, this model was determined to be applicable at time of admission to APCUs and during subsequent days: 81% diagnostic accuracy for the original tree, 80% for cross-validation, and 79% to 84% for subsequent days.
A diagnostic model for impending death within 3 days was developed for patients with cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer